Incyte Corp (INCY)
Incyte develops and sells prescription medicines, mainly for blood cancers and other conditions. It last closed at $119.09 on Nov 17, down 0.98% on the day. INCY reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 13 analysts is $135.00 (+13.4% from the last close), with a high of $157.00 and a low of $108.00. Analyst consensus is Buy, based on the latest ratings from 13 firms (7 buy, 6 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in INCY, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $2.5M, the largest $1.1M.
Key Stats
Last 12 monthsNot reported for this period.
From INCY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 13 analysts who set a price target on INCY in the past 90 days. The average target is $135.00, with a high of $157.00 and a low of $108.00, compared with the last close of $119.09.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Leerink Partners | Target lowered | Buy | $155 → $150 |
| Nov 2 | Bernstein | Target raised | Hold | $99 → $108 |
| Oct 30 | Wells Fargo | Target lowered | Hold | $128 → $127 |
| Oct 30 | RBC Capital | Target raised | Hold | $114 → $117 |
| Oct 30 | Barclays | Target raised | Buy | $139 → $143 |
Technical Analysis
The stock is 0% above its 20 day and 0% above its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 50). The nearest support is the 50 day average at $118.94, and the nearest resistance the Pivot at $119.52.
| RSI (14) | 50.29 | Middle of its range | Neutral |
| MACD | 0.91 | Above its signal line | Bullish |
| Stochastic | 70.3 | Middle of its range | Neutral |
| ADX (14) | 11.3 | No clear trend | |
| Williams %R | -37.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 27.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +1.3% | Change over 10 sessions | Bullish |
| ATR (14) | $3.76 | Typical daily range, 3.2% of price |
| RSI (14) | 55.07 | Middle of its range | Neutral |
| MACD | 3.30 | Below its signal line | Bearish |
| Stochastic | 52.7 | Middle of its range | Neutral |
| ADX (14) | 29.5 | Trending up | |
| Williams %R | -50.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -1.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.0% | Change over 10 sessions | Bearish |
| ATR (14) | $7.70 | Typical daily range, 6.5% of price |
What happened before
See how INCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How INCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in INCY in the last 90 days.
Dark Pool
30DINCY Institutional Ownership
Full report →- ▲499 buying vs 351 selling
- ▼Held by funds -2.1 pts
- ▲Funds holding +37
- ▼Superinvestors: 1 added, 3 cut
- ▼Put/call 0.75 to 4.28
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 899 | 862 | +4.3% |
| In funds' top 10 | 11 | 13 | −15.4% |
| Held by funds | 97.9% | 100.0% | −2.1 pts |
| New / increased | 134 / 365 | 117 / 358 | +5.1% |
| Reduced / sold out | 270 / 81 | 272 / 75 | +1.2% |
| Put/call ratio | 4.28 | 0.75 | +469.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
INCY Stock Buybacks
See all S&P 500 buybacks →From the company's 10-Q filed Oct 29, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INCY is in one of them and how their past INCY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered INCY in an article yet. Here's the latest on the wider market.
INCY Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Ro KhannaD · CA | Sell | $1K – $15K | Oct 7, 2026 | Nov 5, 2026 | 29 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Sep 4, 2026 | Oct 7, 2026 | 33 d |
| Ro KhannaD · CA | Buy | $1K – $15K | May 15, 2026 | Jun 9, 2026 | 25 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Jan 29, 2026 | Feb 6, 2026 | 8 d |
| Ro KhannaD · CA | Buy | $1K – $15K | May 19, 2025 | Jun 12, 2025 | 24 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Incyte
Incyte is a biopharmaceutical company based in Wilmington, Delaware. It discovers, develops and sells prescription medicines, mainly for blood cancers and other conditions, including a topical cream. Physicians prescribe its products to patients, and insurers and other payors decide on coverage. Some of its products are also developed and sold with partners, including Novartis and Lilly.
- Headquarters
- Wilmington, DE
- Founded
- 2001
- Website
- incyte.com ↗








